<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Medical Laboratories &amp; Research</title>
	<atom:link href="http://www.stockbloghub.com/category/medical-laboratories-research/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 16 May 2012 17:53:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(LH) Laboratory Corporation of America Holdings-Orchid Deal Evinces FTC Nod</title>
		<link>http://www.stockbloghub.com/2011/12/09/lh-laboratory-corporation-of-america-holdings-orchid-deal-evinces-ftc-nod/88339</link>
		<comments>http://www.stockbloghub.com/2011/12/09/lh-laboratory-corporation-of-america-holdings-orchid-deal-evinces-ftc-nod/88339#comments</comments>
		<pubDate>Fri, 09 Dec 2011 20:43:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[First Trust Large Cap Gr Opp AlphaDEX]]></category>
		<category><![CDATA[FTC]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[ORCH]]></category>
		<category><![CDATA[Orchid Cellmark Inc.]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88339</guid>
		<description><![CDATA[Laboratory Corporation of America Holdings (LH) received the much awaited nod from the US Federal Trade Commission (FTC) for the proposed acquisition of Orchid Cellmark (ORCH). The FTC nod comes with the rider that LabCorp will have to hive off certain assets of Orchid’s US government paternity business following completion of the transaction. This would reduce the “anti-competitive impact” of the proposed merger, according to the federal agency. LabCorp has agreed to sell those assets to DNA Diagnostics Center, an Ohio based privately held provider of DNA paternity testing. The pending issue with FTC dates back to May 2011. The company’s tender offer for Orchid is scheduled to expire today, unless extended further. LabCorp had decided in April 2011 to acquire Orchid for $2.80 per share, coming to a total ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/09/lh-laboratory-corporation-of-america-holdings-orchid-deal-evinces-ftc-nod/88339/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LH) Laboratory Corporation of America Holdings Extends Orchid Bid Again</title>
		<link>http://www.stockbloghub.com/2011/12/07/lh-laboratory-corporation-of-america-holdings-extends-orchid-bid-again/88036</link>
		<comments>http://www.stockbloghub.com/2011/12/07/lh-laboratory-corporation-of-america-holdings-extends-orchid-bid-again/88036#comments</comments>
		<pubDate>Wed, 07 Dec 2011 17:53:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[First Trust Large Cap Gr Opp AlphaDEX]]></category>
		<category><![CDATA[FTC]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[ORCH]]></category>
		<category><![CDATA[Orchid Cellmark Inc.]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88036</guid>
		<description><![CDATA[Laboratory Corporation of America Holdings (LH) has once again extended the tender offer for Orchid Cellmark (ORCH) until December 9, 2011. The company had earlier extended the tender offer to November 30. In May 2011, the company received a request from the Federal Trade Commission (FTC) for some additional information related to the transaction. LabCorp is cooperating with the FTC on this issue. To date, about 88.2% of the outstanding shares of Orchid have been tendered. LabCorp had decided in April 2011 to acquire Orchid Cellmark for $2.80 per share, coming to a total consideration of $85.4 million, all in cash. After taking into account Orchid Cellmark’s cash balance, LabCorp’s net payable comes to $65.6 million. Orchid Cellmark provides DNA testing services targeted towards forensic and family relationship applications on ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/lh-laboratory-corporation-of-america-holdings-extends-orchid-bid-again/88036/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PPDI) Pharmaceutical Product Development Shareholders Nod to Merger</title>
		<link>http://www.stockbloghub.com/2011/12/06/ppdi-pharmaceutical-product-development-shareholders-nod-to-merger/87968</link>
		<comments>http://www.stockbloghub.com/2011/12/06/ppdi-pharmaceutical-product-development-shareholders-nod-to-merger/87968#comments</comments>
		<pubDate>Tue, 06 Dec 2011 19:34:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[Claymore-Zacks Country Rotation]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Pharmaceutical Product Development Inc]]></category>
		<category><![CDATA[PPDI]]></category>
		<category><![CDATA[UBS]]></category>
		<category><![CDATA[UBS AG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87968</guid>
		<description><![CDATA[Pharmaceutical drug research company Pharmaceutical Product Development, Inc. (PPDI) recently announced that its shareholders have approved the merger with privately held firms The Carlyle Group and Hellman &#38; Friedman. The merger was announced in October 2011. PPD shareholders have been offered a cash consideration of $33.25 per share. The total purchase consideration comes to $3.9 billion in cash. The merger is now subject to certain closing conditions and is expected to close before the end of 2011, following which PPD will become a private company and will no longer trade on NASDAQ. Four banks have committed to finance the deal. These include Credit Suisse (CS), JP Morgan (JPM), Goldman Sachs (GS) and UBS (UBS). Because of the buyout, PPD did not hold a conference call to discuss the third quarter ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/06/ppdi-pharmaceutical-product-development-shareholders-nod-to-merger/87968/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GHDX) Genomic Health to Showcase Key Data</title>
		<link>http://www.stockbloghub.com/2011/12/01/ghdx-genomic-health-to-showcase-key-data/87809</link>
		<comments>http://www.stockbloghub.com/2011/12/01/ghdx-genomic-health-to-showcase-key-data/87809#comments</comments>
		<pubDate>Thu, 01 Dec 2011 15:13:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>
		<category><![CDATA[Natural Gas Services Group Inc]]></category>
		<category><![CDATA[NGS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87809</guid>
		<description><![CDATA[Genomic Health (GHDX), an oncology based biotech company, will present results from 16 studies at the San Antonio Breast Cancer Symposium in December. The company has been recording robust revenue growth over the last few quarters banking on its flagship product, Oncotype DX breast cancer test. The test is used for early stage breast cancer patients to predict the likelihood of cancer recurrence, patient survival within 10 years of diagnosis and chemotherapy benefit. Although the Oncotype DX colon cancer test was launched in 2010, it is yet to make a significant contribution to the top line. Genomic Health has undertaken several studies to expand the use of Oncotype DX. The company is studying the utility of the Oncotype DX test in patients with ductal carcinoma in situ (DCIS). Preliminary results ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/01/ghdx-genomic-health-to-showcase-key-data/87809/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DGX) The Future of Healthcare &#8211; Personalized Medicine</title>
		<link>http://www.stockbloghub.com/2011/11/10/dgx-the-future-of-healthcare-personalized-medicine/86765</link>
		<comments>http://www.stockbloghub.com/2011/11/10/dgx-the-future-of-healthcare-personalized-medicine/86765#comments</comments>
		<pubDate>Thu, 10 Nov 2011 17:54:49 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[LULU]]></category>
		<category><![CDATA[Lululemon Athletica Inc]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>
		<category><![CDATA[UNFI]]></category>
		<category><![CDATA[United Natural Foods Inc.]]></category>
		<category><![CDATA[WFMI]]></category>
		<category><![CDATA[Whole Foods Market Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86765</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, November 9, 2011: Issue #1639 I just got back from my annual physical. Fortunately, everything was fine. But my experience solidified my belief that one of the major healthcare trends that will emerge is the concept of personalized medicine. I had been going to the same doctor every year since 2003. He’s a good guy and has helped me when I’ve been sick. But when I went for my physical every year, he’d tell me to watch my cholesterol, turn my head and cough, and that was pretty much the end of it. This year, I changed doctors. The practice I go to takes a more holistic approach. No, they’re not burning incense and the place doesn’t smell like patchouli. They’re still ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/10/dgx-the-future-of-healthcare-personalized-medicine/86765/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LH) Laboratory Corporation of America Holdings Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2011/11/03/lh-laboratory-corporation-of-america-holdings-earnings-scorecard/86241</link>
		<comments>http://www.stockbloghub.com/2011/11/03/lh-laboratory-corporation-of-america-holdings-earnings-scorecard/86241#comments</comments>
		<pubDate>Thu, 03 Nov 2011 15:12:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[CI]]></category>
		<category><![CDATA[CIGNA Corporation]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[HUM]]></category>
		<category><![CDATA[Humana Inc.]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>
		<category><![CDATA[WellPoint Inc.]]></category>
		<category><![CDATA[WLP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86241</guid>
		<description><![CDATA[The announcement of Laboratory Corporation of America Holdings’ (LH) third quarter fiscal 2011 results, as on October 20, 2011, has led analysts to revise their estimates lower for the fourth quarter and fiscal 2011. Third Quarter Highlights LabCorp reported adjusted EPS of $1.61 (excluding amortization, restructuring and other special charges) for the third quarter of fiscal 2011. The result was higher than the Zacks Consensus Estimate of $1.60 and the previous year&#8217;s adjusted EPS of $1.58. Revenues increased 10% year over year to $1,404.5 million, marginally missing the Zacks Consensus Estimate of $1,408 million. Testing volume (measured by requisitions) and revenue per requisition increased 2.1% and 7.8%, respectively. LabCorp updated its guidance for fiscal 2011. The company now expects a 10.5?11% revenue growth (previous guidance of 9.5?11.5%) resulting in adjusted EPS ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/03/lh-laboratory-corporation-of-america-holdings-earnings-scorecard/86241/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PPDI) Pharmaceutical Product Development to Go Private</title>
		<link>http://www.stockbloghub.com/2011/10/11/ppdi-pharmaceutical-product-development-to-go-private/84787</link>
		<comments>http://www.stockbloghub.com/2011/10/11/ppdi-pharmaceutical-product-development-to-go-private/84787#comments</comments>
		<pubDate>Tue, 11 Oct 2011 15:39:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[Claymore-Zacks Country Rotation]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Pharmaceutical Product Development Inc]]></category>
		<category><![CDATA[PPDI]]></category>
		<category><![CDATA[UBS]]></category>
		<category><![CDATA[UBS AG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84787</guid>
		<description><![CDATA[Pharmaceutical drug research company Pharmaceutical Product Development, Inc. (PPDI) recently announced that it has entered into an agreement to be acquired by privately held The Carlyle Group and Hellman &#38; Friedman for $3.9 billion in cash. PPD shareholders have been offered a cash consideration of $33.25 per share, a premium of 29.6% over the stock’s closing price on September 30. The transaction has won unanimous approval of PPD’s board while shareholder approval is awaited. The transaction is expected to close in the fourth quarter of 2011, following which PPD will become a private company and will no longer trade on NASDAQ. Four banks have committed to finance the deal. These include Credit Suisse, JP Morgan (JPM), Goldman Sachs (GS) and UBS (UBS). PPD has 30 days to solicit superior proposals ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/11/ppdi-pharmaceutical-product-development-to-go-private/84787/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PPDI) Pharmaceutical Product Development Hires New CEO</title>
		<link>http://www.stockbloghub.com/2011/09/24/ppdi-pharmaceutical-product-development-hires-new-ceo/84028</link>
		<comments>http://www.stockbloghub.com/2011/09/24/ppdi-pharmaceutical-product-development-hires-new-ceo/84028#comments</comments>
		<pubDate>Sat, 24 Sep 2011 18:54:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[Claymore-Zacks Country Rotation]]></category>
		<category><![CDATA[CNOOC Limited]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[Pharmaceutical Product Development Inc]]></category>
		<category><![CDATA[PPDI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84028</guid>
		<description><![CDATA[Pharmaceutical Product Development, Inc. (PPDI) recently announced the appointment of Mr. Raymond Hill as its new Chief Executive Officer (CEO) and also a member of the Board of Directors effective from September 16. Raymond Hill was the president of IMS Consulting Group at IMS Health Inc. Prior to joining IMS Health, Mr. Hill served as a senior vice president for Acumen Sciences Limited. PPD also recently announced expansion of its clinical microbiology laboratory globally to strengthen its laboratory services in infectious diseases to meet growing client demand. With the expansion, PPD can offer a full range of microbiology testing services such as bacteriology, mycobacteriology and testing of microbioterrorism pathogens. Our Recommendation We currently have a Hold recommendation on PPD. The company retains a Zacks #3 Rank, which translates into a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/24/ppdi-pharmaceutical-product-development-hires-new-ceo/84028/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LH) Laboratory Corporation of America Holdings-UnitedHealth Extend Pact</title>
		<link>http://www.stockbloghub.com/2011/09/15/lh-laboratory-corporation-of-america-holdings-unitedhealth-extend-pact/83046</link>
		<comments>http://www.stockbloghub.com/2011/09/15/lh-laboratory-corporation-of-america-holdings-unitedhealth-extend-pact/83046#comments</comments>
		<pubDate>Thu, 15 Sep 2011 17:48:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[CI]]></category>
		<category><![CDATA[CIGNA Corporation]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>
		<category><![CDATA[WellPoint Inc.]]></category>
		<category><![CDATA[WLP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83046</guid>
		<description><![CDATA[Last week, Laboratory Corporation of America Holdings (LH) announced that it has extended its agreement with UnitedHealthcare Insurance Company, an affiliate of UnitedHealth Group (UNH). The agreement, effective since January 1, 2007, will continue until 2018. Under the terms of the agreement, LabCorp will continue to be the national laboratory for UnitedHealthcare and Oxford Health Plans and the exclusive laboratory provider for some HMO benefit plans. In 2006, LabCorp had entered into a 10-year agreement with UnitedHealthcare to become its exclusive national laboratory. The company continues to work closely with MCOs by providing value-added services. The growth of the managed care sector and consolidation have presented various challenges and opportunities to several independent clinical laboratories. Last year, LabCorp extended its contracts with Wellpoint Inc. (WLP) and Cigna Corporation (CI) through ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/15/lh-laboratory-corporation-of-america-holdings-unitedhealth-extend-pact/83046/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DGX) Quest Diagnostics Seeks Regular Colon Test</title>
		<link>http://www.stockbloghub.com/2011/06/29/dgx-quest-diagnostics-seeks-regular-colon-test/77779</link>
		<comments>http://www.stockbloghub.com/2011/06/29/dgx-quest-diagnostics-seeks-regular-colon-test/77779#comments</comments>
		<pubDate>Wed, 29 Jun 2011 16:37:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[FIT]]></category>
		<category><![CDATA[Health Fitness Corporation]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77779</guid>
		<description><![CDATA[Leading diagnostics player Quest Diagnostics (DGX) is dissatisfied with the outcome of a nationwide study that it had carried out along with the Colon Cancer Alliance. The data demonstrated that one in three of men and women aged 60-70 have been screened for colon cancer only once. However, the medical guidelines suggest periodic testing after initial screening at age 50 by colonoscopy and other methods. Recommended screening tests include colonoscopy (every 10 years), flexible sigmoidoscopy or virtual colonoscopy (every five years), and fecal occult blood (FOBT) and fecal immunochemical (FIT) tests (annually). Screening at regular intervals is significant as colon cancer is the second leading cause of cancer death in the US. However, it is often treatable when detected in early stages. According to the US Centers for Disease Control ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/dgx-quest-diagnostics-seeks-regular-colon-test/77779/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DGX) Quest Diagnostics Launches Gazelle on Android</title>
		<link>http://www.stockbloghub.com/2011/06/23/dgx-quest-diagnostics-launches-gazelle-on-android/77247</link>
		<comments>http://www.stockbloghub.com/2011/06/23/dgx-quest-diagnostics-launches-gazelle-on-android/77247#comments</comments>
		<pubDate>Thu, 23 Jun 2011 16:08:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[GOOG]]></category>
		<category><![CDATA[Google Inc.]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>
		<category><![CDATA[Research In Motion Limited]]></category>
		<category><![CDATA[RIMM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77247</guid>
		<description><![CDATA[Quest Diagnostics (DGX),a leading player in the diagnostic testing market, recently launched a new version of its mobile health platform, Gazelle. The company claims that this latest version will work in sync with Google’s (GOOG) fast-growing Android smartphone operating system. Currently, Gazelle is available for free at Gazelleapp.com as well as in the Android Market at market.android.com. Earlier, in October 2010, Gazelle was first introduced to operate under Apple’s (AAPL) iPhone and Research In Motion’s (RIMM) BlackBerry platforms. This application enables the patients to see, store and share their vital health information including Quest Diagnostics laboratory test results with the healthcare providers via mail or fax. With the latest version of Gazelle, which is compatible with Google Android, users in 33 states including the District of Columbia will be able ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/23/dgx-quest-diagnostics-launches-gazelle-on-android/77247/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LH) Laboratory Corporation of America Holdings Extends Orchid Tender Offer</title>
		<link>http://www.stockbloghub.com/2011/06/19/lh-laboratory-corporation-of-america-holdings-extends-orchid-tender-offer/76735</link>
		<comments>http://www.stockbloghub.com/2011/06/19/lh-laboratory-corporation-of-america-holdings-extends-orchid-tender-offer/76735#comments</comments>
		<pubDate>Sun, 19 Jun 2011 13:34:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[First Trust Large Cap Gr Opp AlphaDEX]]></category>
		<category><![CDATA[FTC]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[ORCH]]></category>
		<category><![CDATA[Orchid Cellmark Inc.]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76735</guid>
		<description><![CDATA[Laboratory Corporation of America Holdings (LH) has decided to extend the tender offer for Orchid Cellmark (ORCH) till July 15, 2011. Earlier, in May 2011, the company received a request from the Federal Trade Commission (FTC) for some additional information related to the transaction. LabCorp is cooperating with the FTC on this issue. Till date about 88.2% of the outstanding shares of Orchid have been tendered. In April, LabCorp had decided to acquire Orchid Cellmark for $2.80 per share in cash or a total $85.4 million. After taking into account Orchid Cellmark’s cash balance LabCorp’s net payable comes to $65.6 million. Orchid Cellmark provides DNA testing services targeted towards forensic and family relationship applications on a global basis. Based on this deal, LabCorp will be able to develop a command ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/19/lh-laboratory-corporation-of-america-holdings-extends-orchid-tender-offer/76735/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PPDI) Pharmaceutical Product Development Misses Estimates by a Penny</title>
		<link>http://www.stockbloghub.com/2011/05/03/ppdi-pharmaceutical-product-development-misses-estimates-by-a-penny/72677</link>
		<comments>http://www.stockbloghub.com/2011/05/03/ppdi-pharmaceutical-product-development-misses-estimates-by-a-penny/72677#comments</comments>
		<pubDate>Tue, 03 May 2011 19:09:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[Claymore-Zacks Country Rotation]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[Pharmaceutical Product Development Inc]]></category>
		<category><![CDATA[PPDI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72677</guid>
		<description><![CDATA[Pharmaceutical Product Development, Inc. (PPDI) reported first quarter 2011 earnings of 32 cents per share, above the year-ago earnings of 14 cents per share. Earnings growth was driven by higher revenue, improved gross margins and reduced SG&#38;A expenses. Earnings however came a penny below the Zacks Consensus Estimate of 33 cents. Quarterly revenue of $383.2 million was up 10.5% over the prior-year period and also ahead of the Zacks Consensus Estimate of $360 million. Revenue growth was driven by strong performance of the Clinical Development segment. The Quarter in Detail The company operates through two segments &#8211; Clinical Development Services and Laboratory Services Clinical Development Services: The segment includes global phase II-IV clinical trial management services.  In the first quarter, the segment revenue was $279.7 million, up 12.2% over the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/03/ppdi-pharmaceutical-product-development-misses-estimates-by-a-penny/72677/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DGX) Quest Diagnostics Expedites Celera Acquisition</title>
		<link>http://www.stockbloghub.com/2011/04/15/dgx-quest-diagnostics-expedites-celera-acquisition/71625</link>
		<comments>http://www.stockbloghub.com/2011/04/15/dgx-quest-diagnostics-expedites-celera-acquisition/71625#comments</comments>
		<pubDate>Fri, 15 Apr 2011 17:01:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Celera Corporation]]></category>
		<category><![CDATA[CRA]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71625</guid>
		<description><![CDATA[Leading diagnostics player, Quest Diagnostics (DGX) took a step forward toward the proposed acquisition of Celera Corporation (CRA). The company recently announced that the waiting period under the HSR Act has expired, though some other conditions are yet to be met. The tender offer to acquire the shares of Celera is supposed to close on April 25, 2011, unless extended further. Last month, Quest decided to acquire Celera for $8 per share, through which the company plans to strengthen its footing in molecular diagnostics discovery and development. Celera’s proprietary genetic tests, pipeline of biomarkers, along with esoteric cardiovascular test, offered by Berkeley HeartLab should drive Quest’s revenues. Celera, with revenues of $128 million in 2010, is expected to add just over 1% to Quest’s 2011 revenue growth. The transaction, to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/15/dgx-quest-diagnostics-expedites-celera-acquisition/71625/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DGX) Quest Diagnostics &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2010/08/02/dgx-quest-diagnostics-bear-of-the-day/45587</link>
		<comments>http://www.stockbloghub.com/2010/08/02/dgx-quest-diagnostics-bear-of-the-day/45587#comments</comments>
		<pubDate>Mon, 02 Aug 2010 14:51:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=45587</guid>
		<description><![CDATA[Quest Diagnostics (DGX) second-quarter EPS of $0.89 beats the Zacks Consensus Estimate by a penny and the year-ago quarters by 7 cents. However, revenues declined 1.4% to $1.9 billion, driven by a decline in both volume and pricing. Meanwhile, the company proactively negotiated contracts with some MCOs at reduced prices. Although this gives more visibility, revenue per requisition was affected in the near term. Quest is adopting strategies such as suitable acquisitions Incorporatedreased sales force and targeting additional geographies to drive its top line. However, we believe in the near term volume and pricing outlook will continue to remain under pressure unless the economic scenario improves. As a result, we lower our estimates for the company and downgrade it to Underperform. Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/02/dgx-quest-diagnostics-bear-of-the-day/45587/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GHDX) Genomic Heath Incorporated &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2010/07/23/ghdx-genomic-heath-incorporated-bear-of-the-day/44372</link>
		<comments>http://www.stockbloghub.com/2010/07/23/ghdx-genomic-heath-incorporated-bear-of-the-day/44372#comments</comments>
		<pubDate>Fri, 23 Jul 2010 15:09:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44372</guid>
		<description><![CDATA[Genomic Health&#8217;s (GHDX) first quarter 2010 loss of $0.07 per share missed the Zacks Consensus Estimate of a loss of $0.03. Although the company&#8217;s lead product, Oncotype DX breast cancer test, recorded a year-over-year growth of 20%, revenues declined sequentially. Meanwhile, Genomic launched its colon cancer test in January 2010, though this test will take a fair amount of time before contributing significantly to the top line. As a result, the company is solely dependent on the breast cancer test. Moreover, we are concerned about the outcome of the FDA meeting on LDTs, the outcome of which might have a long-term impact on the company. Other pipeline tests at Genomic have a long way to go before commercialization, as well. Given these factors, we downgrade the stock to Underperform. We ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/23/ghdx-genomic-heath-incorporated-bear-of-the-day/44372/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LH) LabCorp First Quarter 2010 Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2010/05/23/lh-labcorp-first-quarter-2010-earnings-scorecard/38004</link>
		<comments>http://www.stockbloghub.com/2010/05/23/lh-labcorp-first-quarter-2010-earnings-scorecard/38004#comments</comments>
		<pubDate>Mon, 24 May 2010 04:13:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=38004</guid>
		<description><![CDATA[First Quarter Highlights On April 21, LabCorp (LH) reported first quarter fiscal 2010 earnings per share (EPS) of $1.25 compared with earnings of $1.22 in the year-ago period. However, after considering restructuring and other special charges, the company’s EPS came in at $1.30, missing the Zacks Consensus Estimate by a penny. Revenues recorded a 3.3% year-over-year increase to $1.19 billion. During the quarter, there was a 3% decline in testing volume (measured by accessions) while revenue per requisition increased 6.4%. However, excluding the consolidation of the company’s Canada unit, revenues would have increased 2.2%; testing volume would have declined 3.3% while revenue per requisition would have recorded a growth of 5.7%. In addition, LabCorp reiterated its guidance for 2010. The company expects EPS in the range of $5.35–$5.55 with a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/23/lh-labcorp-first-quarter-2010-earnings-scorecard/38004/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GHDX) Genomic Health&#8217;s Loss Wider Than Expected</title>
		<link>http://www.stockbloghub.com/2010/05/06/ghdx-genomic-healths-loss-wider-than-expected/36425</link>
		<comments>http://www.stockbloghub.com/2010/05/06/ghdx-genomic-healths-loss-wider-than-expected/36425#comments</comments>
		<pubDate>Thu, 06 May 2010 20:31:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36425</guid>
		<description><![CDATA[Genomic Health Inc’s (GHDX) first quarter 2010 loss of 7 cents per share was wider than the Zacks Consensus Estimate of a net loss of 3 cents. The company had suffered a loss of 16 cents in the prior-year period. Total revenues for the reported quarter came in at $41.2 million as against $33.9 million in the year-ago quarter, up 21.5% year over year. Product revenues from the Oncotype DX breast cancer test climbed approximately 20% year over year to $40.3 million in the first quarter of 2010. Contract revenues accounted for the balance. In the first quarter of 2010, Genomic Health delivered in excess of 13,310 test results, as against more than 11,210 test results in the comparable period of 2009, representing approximately a 19% year-over-year growth. Research and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/06/ghdx-genomic-healths-loss-wider-than-expected/36425/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARRY) Array BioPharma and Novartis AG Sign Deal for Treating Cancer</title>
		<link>http://www.stockbloghub.com/2010/04/22/arry-array-biopharma-and-novartis-ag-sign-deal-for-treating-cancer/34746</link>
		<comments>http://www.stockbloghub.com/2010/04/22/arry-array-biopharma-and-novartis-ag-sign-deal-for-treating-cancer/34746#comments</comments>
		<pubDate>Thu, 22 Apr 2010 21:27:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Array BioPharma]]></category>
		<category><![CDATA[ARRY]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34746</guid>
		<description><![CDATA[Recently, Array BioPharma Inc. (ARRY) struck a deal with Novartis AG (NVS) to develop its small-molecule methyl ethyl ketone (MEK) inhibitors for treating cancer. The transaction is worth up to $467 million. Array is entitled to receive $45 million in upfront and milestone payments and a further $422 million subject to the achievement of other milestones. The global agreement pertains to the development of ARRY-162, ARRY-300 and other MEK inhibitors. ARRY-162 is currently undergoing early-stage development. The open-label, multiple dose trial is designed to determine the maximum tolerated dose apart from evaluating the safety, pharmacokinetics and pharmacodynamics of the candidate after daily oral administration in advanced cancer patients with solid tumors. The study has established a maximum tolerated dose. Array has started an expansion phase of this trial initially in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/22/arry-array-biopharma-and-novartis-ag-sign-deal-for-treating-cancer/34746/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LH) Laboratory Corporation of America Holdings Misses by a Penny</title>
		<link>http://www.stockbloghub.com/2010/04/22/lh-laboratory-corporation-of-america-holdings-misses-by-a-penny/34617</link>
		<comments>http://www.stockbloghub.com/2010/04/22/lh-laboratory-corporation-of-america-holdings-misses-by-a-penny/34617#comments</comments>
		<pubDate>Thu, 22 Apr 2010 20:10:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Unitedhealth Group]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34617</guid>
		<description><![CDATA[Laboratory Corporation of America Holdings (LH) reported first quarter fiscal 2010 earnings per share (EPS) of $1.25 compared to earnings of $1.22 reported in the year-ago period. However, after considering restructuring and other special charges, the company’s EPS came in at $1.30, missing the Zacks Consensus Estimate by a penny. Revenues recorded a 3.3% year-over-year increase to $1.19 billion. During the reported quarter, there was a 3% decline in testing volume (measured by accessions) while revenue per requisition increased 6.4%. However, excluding the consolidation of Quest’s Canada unit, revenues would have increased 2.2%, testing volume would have declined 3.3% while revenue per requisition would have recorded a growth of 5.7%. During the quarter, bad weather conditions had an adverse impact on the company. It reduced volume by 1.3%, revenues by ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/22/lh-laboratory-corporation-of-america-holdings-misses-by-a-penny/34617/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DGX) Quest Diagnostics Beats Expectations but Revenues are Unchanged</title>
		<link>http://www.stockbloghub.com/2010/04/21/dgx-quest-diagnostics-beats-expectations-but-revenues-are-unchanged/34559</link>
		<comments>http://www.stockbloghub.com/2010/04/21/dgx-quest-diagnostics-beats-expectations-but-revenues-are-unchanged/34559#comments</comments>
		<pubDate>Wed, 21 Apr 2010 20:58:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34559</guid>
		<description><![CDATA[Quest Diagnostics (DGX) reported first quarter fiscal 2010 earnings per share (EPS) of 89 cents, unchanged from the year-ago period. However, excluding the impact of severe weather conditions and charges associated with workforce reduction Quest’s EPS came in at $1.00, beating the Zacks Consensus Estimate by a couple of cents. Revenues for the quarter remained unchanged at $1.8 billion. However, the EPS improved compared to the year-ago period due to the 4.4% reduction in the number of outstanding shares. Clinical testing revenues, which account for most of Quest’s sales, declined 0.4% compared to the prior year. While underlying volume in clinical testing (measured by the number of requisitions) during the quarter declined 2.6%, revenue per requisition increased 2.3% compared to the year-ago period. Quest witnessed increased demand for gene-based and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/21/dgx-quest-diagnostics-beats-expectations-but-revenues-are-unchanged/34559/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DGX) Why Healthcare Reform Should Help The Diagnostics Industry</title>
		<link>http://www.stockbloghub.com/2010/04/01/dgx-why-healthcare-reform-should-help-the-diagnostics-industry/32633</link>
		<comments>http://www.stockbloghub.com/2010/04/01/dgx-why-healthcare-reform-should-help-the-diagnostics-industry/32633#comments</comments>
		<pubDate>Thu, 01 Apr 2010 21:37:50 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Bio-Reference Laboratories Inc]]></category>
		<category><![CDATA[BRLI]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[Genoptix]]></category>
		<category><![CDATA[GHDX]]></category>
		<category><![CDATA[GXDX]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32633</guid>
		<description><![CDATA[America seems to be divided into two camps… Not blue states versus red states. Not Yankees fans versus Red Sox fans (although why you’d be the latter I’ll never understand). Not even people who support the new healthcare reform bill versus those who are opposed to it. Rather, I’m talking about the difference between people who run to the doctor for every little ache and pain, compared with those who wouldn’t go within 50 yards of a doctor’s office even if their internal organs suddenly became external… The Diagnostics Industry: More Healthcare Coverage Means More Business My family and I try to stay out of doctor’s offices. This has been the case, ever since a routine visit to get my six-year-old son some orthopedics in his shoes turned into scheduled ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/01/dgx-why-healthcare-reform-should-help-the-diagnostics-industry/32633/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GHDX) Genomic Health Announces New Distribution Deal</title>
		<link>http://www.stockbloghub.com/2010/03/29/ghdx-genomic-health-announces-new-distribution-deal/32185</link>
		<comments>http://www.stockbloghub.com/2010/03/29/ghdx-genomic-health-announces-new-distribution-deal/32185#comments</comments>
		<pubDate>Mon, 29 Mar 2010 20:52:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32185</guid>
		<description><![CDATA[Recently, Genomic Health, Inc. (GHDX) announced that it has agreed to distribute its breast cancer assay Oncotype DX with Palex Medical S.A. in Spain and Portugal. The company also announced encouraging data on Oncotype DX at the 7th European Breast Cancer Conference in Barcelona. The deal with Palex Medical, a leading player in the distribution of medical devices in Spain and Portugal, further expands the international presence of Genomic Health’s lead product. The transaction aims to provide physicians and patients with increased access to this advanced diagnostic test in the European market. As of December 2009, more than 8,000 physicians had ordered in excess of 135,000 Oncotype DX tests in over 55 countries. In addition to the agreement, Genomic Health announced data from two studies which further underline the benefits ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/ghdx-genomic-health-announces-new-distribution-deal/32185/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BRLI) Bio-Reference Labs &#8211; Analysts React By Raising Estimates</title>
		<link>http://www.stockbloghub.com/2010/03/29/brli-bio-reference-labs-analysts-react-by-raising-estimates/32105</link>
		<comments>http://www.stockbloghub.com/2010/03/29/brli-bio-reference-labs-analysts-react-by-raising-estimates/32105#comments</comments>
		<pubDate>Mon, 29 Mar 2010 16:45:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Bio-Reference Laboratories Inc]]></category>
		<category><![CDATA[BRLI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32105</guid>
		<description><![CDATA[Bio-Reference Labs (BRLI) recently beat earnings estimates once again. Shares are up roughly 10% since being featured as a Zacks Rank Buy in December. Company Description Bio-Reference Laboratories, provides clinical laboratory testing services such as blood and urine analysis in the New York metropolitan area. The company was founded in 1981 and has a market cap of $536 million. Another Surprise On Mar 4 Bio-Reference reported first-quarter results that included a 31% jump in revenue. The growth came on over patient growth as well as revenue per patient. Earnings per shares came in at 29 cents, 6 cents ahead of expectations. Bio-Referance has now topped estimates 7 times in a row. Analysts React Bio-Reference analysts raised their estimates following the news. The Zacks Consensus Estimate for fiscal 2010 is up ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/brli-bio-reference-labs-analysts-react-by-raising-estimates/32105/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SPEX) Initiating Spherix Analyst Coverage at Outperform</title>
		<link>http://www.stockbloghub.com/2010/02/09/spex-initiating-spherix-analyst-coverage-at-outperform/27462</link>
		<comments>http://www.stockbloghub.com/2010/02/09/spex-initiating-spherix-analyst-coverage-at-outperform/27462#comments</comments>
		<pubDate>Tue, 09 Feb 2010 21:35:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[SPEX]]></category>
		<category><![CDATA[Spherix Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27462</guid>
		<description><![CDATA[We are initiating coverage of Spherix, Inc. (SPEX) with an Outperform rating and price target of $3.50 per share. We are optimistic about D-tagatose, a functional sweetener and a naturally occurring L-epimer of D-Fructose currently under phase III development for the treatment of type 2 diabetes. D-tagatose, or Naturlose as it is branded, was originally developed as a natural sugar-substitute (sweetener) for food and OTC product applications. The molecule has a similar taste and texture to sucrose (table sugar), is 92% as sweet, but has only 38% of the calories. Spherix used chiral carbohydrate research to create L-sugars that would not be metabolized by the body, but would retain sweetness. The body lacks the enzyme necessary to efficiently metabolize this molecule, and thus it is poorly absorbed in the small ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/09/spex-initiating-spherix-analyst-coverage-at-outperform/27462/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARRY) Array BioPharma Incorporated Reports Lower Second Quarter Loss</title>
		<link>http://www.stockbloghub.com/2010/02/02/arry-array-biopharma-incorporated-reports-lower-second-quarter-loss/26820</link>
		<comments>http://www.stockbloghub.com/2010/02/02/arry-array-biopharma-incorporated-reports-lower-second-quarter-loss/26820#comments</comments>
		<pubDate>Wed, 03 Feb 2010 01:37:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Array BioPharma]]></category>
		<category><![CDATA[ARRY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26820</guid>
		<description><![CDATA[Array BioPharma Inc’s (ARRY) second quarter fiscal 2010 net loss came in at $21.8 million, or 44 cents per share, which was lower than the Zacks Consensus Estimate of a net loss of 55 cents. The company suffered a loss of $37.8 million, or 79 cents a share, in the year-ago quarter. The narrower loss in the quarter was attributable to increased revenues coupled with lower operating expenses. Quarterly Results Total revenue for the quarter came in at $9.6 million, representing approximately a 25% increase from the year-ago quarter. Array&#8217;s license and milestone revenue for the quarter increased to $5.2 million from $2.6 million while collaboration revenue fell to $4.4 million in the quarter, down 12%. Total operating expenses in the quarter declined to $28.8 million from $33.2 million. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/02/arry-array-biopharma-incorporated-reports-lower-second-quarter-loss/26820/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DGX) Quest Diagnostics Beats Expectations &#8211; Guides In-Line</title>
		<link>http://www.stockbloghub.com/2010/01/25/dgx-quest-diagnostics-beats-expectations-guides-in-line/25900</link>
		<comments>http://www.stockbloghub.com/2010/01/25/dgx-quest-diagnostics-beats-expectations-guides-in-line/25900#comments</comments>
		<pubDate>Mon, 25 Jan 2010 20:52:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25900</guid>
		<description><![CDATA[Quest Diagnostics’ (DGX) fourth quarter earnings per share of 97 cents beat both the Zacks Consensus Estimate by a penny and the 87 cents reported in the year-ago period. Revenues for the quarter increased 2.7% to $1.8 billion. Clinical testing revenues, which account for most of Quest’s sales Incorporatedreased 2.3% compared to the prior year. For the full year, while revenues increased 2.8% to $7.5 billion, earnings per share recorded a rise of 20% to $3.88. The growth in revenues was primarily driven by increased demand for innovative gene-based and esoteric tests Incorporatedluding cancer diagnostics. Among the latest initiatives, the company introduced a new blood test that identifies changes in DNA associated with colorectal cancer. While underlying volume in clinical testing (measured by the number of requisitions) during the quarter ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/25/dgx-quest-diagnostics-beats-expectations-guides-in-line/25900/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GHDX) Genomic Health Announces Commercial Availability Of Its Oncotype DX Colon Cancer Test</title>
		<link>http://www.stockbloghub.com/2010/01/23/ghdx-genomic-health-announces-commercial-availability-of-its-oncotype-dx-colon-cancer-test/25804</link>
		<comments>http://www.stockbloghub.com/2010/01/23/ghdx-genomic-health-announces-commercial-availability-of-its-oncotype-dx-colon-cancer-test/25804#comments</comments>
		<pubDate>Sat, 23 Jan 2010 21:18:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25804</guid>
		<description><![CDATA[Recently, Genomic Health, Inc. (GHDX) announced the global commercial availability of its Oncotype DX colon cancer test. The 12-gene diagnostic test aims to predict individual recurrence risk in stage II colon cancer patients after surgery. The Genomic Health test is the first multigene expression test developed for assessing the risk of recurrence in patients suffering from stage II colon cancer. Stage II colon cancer (also known as Dukes&#8217; Stage B) affects approximately 30,000 -40,000 people annually in the United States and the current treatment paradigm is not very clear. About a third of the patients receive chemotherapy post surgery. However, research indicates that chemotherapy benefits only 2% to 4% of patients. Furthermore, the treatment has significant associated toxicity. The decision to treat patients with chemotherapy post surgery is based on ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/23/ghdx-genomic-health-announces-commercial-availability-of-its-oncotype-dx-colon-cancer-test/25804/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GHDX) Genomic Health Provides Revenue Guidance</title>
		<link>http://www.stockbloghub.com/2010/01/08/ghdx-genomic-health-provides-revenue-guidance/24502</link>
		<comments>http://www.stockbloghub.com/2010/01/08/ghdx-genomic-health-provides-revenue-guidance/24502#comments</comments>
		<pubDate>Fri, 08 Jan 2010 21:01:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24502</guid>
		<description><![CDATA[Genomic Health, Inc. (GHDX) announced recently that it is confident of meeting the annual revenue guidance for the fiscal year 2009, ended Dec 31. The company expects to report revenues of $149.5 million for fiscal 2009. This represents a 35% increase on revenues of $110.6 million reported by Genomic Health in fiscal 2008. Genomic Health further announced that it expects to report revenues of $39.5 million in the fourth quarter of fiscal 2009. This represents a 26% increase on revenues of $31.2 million reported by the company in the fourth quarter of 2008. However the preliminary revenues for the quarter would be affected adversely by payment delays of approximately $2.5 million, from Anthem Insurance Companies and the Blue Card program administered by Blue Shield of California. Genomic Health expects to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/08/ghdx-genomic-health-provides-revenue-guidance/24502/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BRLI) Bio-Reference Labs &#8211; Earnings Estimates Are Rising</title>
		<link>http://www.stockbloghub.com/2009/12/30/brli-bio-reference-labs-earnings-estimates-are-rising/23896</link>
		<comments>http://www.stockbloghub.com/2009/12/30/brli-bio-reference-labs-earnings-estimates-are-rising/23896#comments</comments>
		<pubDate>Wed, 30 Dec 2009 21:54:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Bio-Reference Laboratories Inc]]></category>
		<category><![CDATA[BRLI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23896</guid>
		<description><![CDATA[Bio-Reference Laboratories (BRLI) is setting new 52-week highs following its record-breaking quarter. Company Description Bio-Referance Laboratories, provides clinical laboratory testing services such as blood and urine analysis in the New York metropolitan area. The company was founded in 1981 and has a market cap of $536 million. Record-Setting Quarter On Dec 17 the company reported fourth-quarter revenue of $102 million, Bio-Referance&#8217;s highest to date. In the same period last year revenue was $81 million, making this a 26% increase. Net income was up 37%, to $7.2 million. Earnings per share were 51 cents, 7 cents higher than the Zacks Consensus Estimate, making it the sixth consecutive earnings surprise. Sustainable Growth In the same press release, Marc D. Grodman, MD, CEO, said &#8220;All aspects of our business have seen growth over ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/30/brli-bio-reference-labs-earnings-estimates-are-rising/23896/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GXDX) Genoptix, Inc. &#8211; Sales Were up 58% From Last Year</title>
		<link>http://www.stockbloghub.com/2009/12/16/gxdx-genoptix-inc-sales-were-up-58-from-last-year/22958</link>
		<comments>http://www.stockbloghub.com/2009/12/16/gxdx-genoptix-inc-sales-were-up-58-from-last-year/22958#comments</comments>
		<pubDate>Wed, 16 Dec 2009 17:24:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Genoptix Inc.]]></category>
		<category><![CDATA[GXDX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22958</guid>
		<description><![CDATA[Genoptix, Inc. (GXDX) continues to pressure its 52-week high as shares ride a trend line that began this summer higher. The company&#8217;s better than expected third-quarter results, reported on Nov 5, also helped fuel optimism. Company Description Genoptix, Inc. provides specialized laboratory services focusing on diagnostics in the United States. The company was founded in 1999 and has a market cap of $644 million. Third-Quarter Results Sales were up 58% from last year to $50.8 million. Earnings also came in strong at 53 cents per share, 19 cents ahead of the Zacks Consensus Estimate. The company has beat in each of the last four quarters by an average of 13 cents, or 46%. The company benefited from margin expansion and operational efficiencies, with gross margin gaining 2% to 64%. Operating ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/16/gxdx-genoptix-inc-sales-were-up-58-from-last-year/22958/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARRY) Array BioPharma Sees Positive Results for ARRY-380</title>
		<link>http://www.stockbloghub.com/2009/12/14/arry-array-biopharma-sees-positive-results-for-arry-380/22765</link>
		<comments>http://www.stockbloghub.com/2009/12/14/arry-array-biopharma-sees-positive-results-for-arry-380/22765#comments</comments>
		<pubDate>Tue, 15 Dec 2009 01:21:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[ARQL]]></category>
		<category><![CDATA[ArQule Inc]]></category>
		<category><![CDATA[Array BioPharma]]></category>
		<category><![CDATA[ARRY]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22765</guid>
		<description><![CDATA[Recently, Array BioPharma Inc. (ARRY) announced positive interim results on its inhibitor, ARRY-380, from an early-stage, open-label, multiple dose trial in patients with advanced cancer. The company presented the results at the 2009 San Antonio Breast Cancer Symposium. The study is designed to evaluate the safety, tolerability and pharmacokinetics of ARRY-380 following daily oral administration to patients suffering from advanced cancer. The candidate, which has been effective in preclinical models of human breast cancer resulting in significant anti-tumor activity, is a selective, orally-active ErbB-2 inhibitor being evaluated by Array for cancer indications. ErbB-2 is a receptor kinase target that has been found to be over-expressed in breast cancer as well as other cancers like gastric and ovarian cancers. The interim results revealed that ARRY-380 showed evidence of tumor regression in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/14/arry-array-biopharma-sees-positive-results-for-arry-380/22765/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GHDX) Genomic Health, Inc Reveals Oncotype DX Data</title>
		<link>http://www.stockbloghub.com/2009/12/11/ghdx-genomic-health-inc-reveals-oncotype-dx-data/22634</link>
		<comments>http://www.stockbloghub.com/2009/12/11/ghdx-genomic-health-inc-reveals-oncotype-dx-data/22634#comments</comments>
		<pubDate>Fri, 11 Dec 2009 22:48:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22634</guid>
		<description><![CDATA[Genomic Health, Inc. (GHDX) announced that positive results were published in the journal, The Lancet Oncology, from a study of the company’s growth engine, Oncotype DX, in postmenopausal women suffering from node-positive, estrogen receptor-positive breast cancer. The study was conducted by the Southwest Oncology Group (SWOG) and funded by the National Cancer Institute and Genomic Health. The findings were presented at the American Association for Cancer Research San Antonio Breast Cancer Symposium. The study evaluated whether the Oncotype DX test can predict, which women would stand to gain from chemotherapy. The study not only evaluated the efficacy of 21 genes from a tumor but also produced a score that predicts chemotherapy benefit. The analysis suggested that women having a low score on the Oncotype DX test did not appear to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/11/ghdx-genomic-health-inc-reveals-oncotype-dx-data/22634/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GHDX) Genomic Health Third Quarter Loss Narrows</title>
		<link>http://www.stockbloghub.com/2009/11/08/ghdx-genomic-health-third-quarter-loss-narrows/19881</link>
		<comments>http://www.stockbloghub.com/2009/11/08/ghdx-genomic-health-third-quarter-loss-narrows/19881#comments</comments>
		<pubDate>Mon, 09 Nov 2009 02:46:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19881</guid>
		<description><![CDATA[Genomic Health Inc. (GHDX) suffered a third quarter loss of 2 cents per share, which was better than the Zacks Consensus Estimate of a loss of 9 cents. The company suffered a loss of 11 cents in the prior-year period. Total revenues for the quarter came in at $39.5 million, compared with $28.1 million in the third quarter of 2008, up 40.6%. Product revenues from the Oncotype DX breast cancer test increased 39% to $38.9 million, compared with $28.1 million in the comparable quarter of 2008. Contract revenues accounted for the balance. In the third quarter, Genomic Health delivered in excess of 12,600 test results, compared with more than 10,220 test results in the comparable period of 2008, representing approximately a 23% year-over-year growth. Research and development spend for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/08/ghdx-genomic-health-third-quarter-loss-narrows/19881/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DGX) Quest Diagnostics Outperforms &#8211; Raises Outlook</title>
		<link>http://www.stockbloghub.com/2009/10/21/dgx-quest-diagnostics-outperforms-raises-outlook/18377</link>
		<comments>http://www.stockbloghub.com/2009/10/21/dgx-quest-diagnostics-outperforms-raises-outlook/18377#comments</comments>
		<pubDate>Wed, 21 Oct 2009 23:47:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18377</guid>
		<description><![CDATA[Quest Diagnostics’ (DGX) third quarter earnings per share of $1.02 beat the Zacks Consensus Estimate of 96 cents and 86 cents reported in the year ago period. Revenues for the quarter increased 3.9% to $1.9 billion. Clinical testing revenues, which account for most of Quest’s sales increased 4.3% compared to the prior year. Quest Diagnostics witnessed strong testing demand in the areas of cancer, allergies, and vitamin D levels. Among the latest initiatives, the company introduced the first commercial test for the H1N1 flu virus authorized by the US Food and Drug Administration (FDA) for emergency use, and launched a saliva-based genetic test that helps physicians predict response to the blood thinner Plavix. While underlying volume in clinical testing (measured by the number of requisitions), continued to grow in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/21/dgx-quest-diagnostics-outperforms-raises-outlook/18377/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GHDX) Genomic Health&#8217;s Results Reveal Oncotype DX Utility</title>
		<link>http://www.stockbloghub.com/2009/10/14/ghdx-genomic-healths-results-reveal-oncotype-dx-utility/17568</link>
		<comments>http://www.stockbloghub.com/2009/10/14/ghdx-genomic-healths-results-reveal-oncotype-dx-utility/17568#comments</comments>
		<pubDate>Wed, 14 Oct 2009 16:28:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Clarient Inc]]></category>
		<category><![CDATA[CLRT]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17568</guid>
		<description><![CDATA[Recently, Genomic Health Inc. (GHDX) announced data which confirmed that manual micro dissection (dissection of tissue or cells under the microscope) of biopsy cavities is essential for the accurate assessment of recurrence risk in patients with early-stage breast cancer. Genomic Health&#8217;s Oncotype DX is the only commercially available breast cancer test that makes use of manual microdissection following review by a board certified surgical pathologist with expertise in breast cancer to predict a patient&#8217;s benefit from chemotherapy and risk of disease recurrence. The results from the study revealed that the inclusion of biopsy cavities in breast cancer specimens is associated with significant changes in the expression of individual genes. Consequently, it was found that biopsy cavities had high-risk Recurrence Scores. Genomic also presented results which demonstrated ability of Oncotype DX ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/14/ghdx-genomic-healths-results-reveal-oncotype-dx-utility/17568/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARRY) Setback for Array BioPharma&#8217;s Drug</title>
		<link>http://www.stockbloghub.com/2009/09/08/arry-setback-for-array-biopharmas-drug/14607</link>
		<comments>http://www.stockbloghub.com/2009/09/08/arry-setback-for-array-biopharmas-drug/14607#comments</comments>
		<pubDate>Tue, 08 Sep 2009 23:24:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Array BioPharma]]></category>
		<category><![CDATA[ARRY]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14607</guid>
		<description><![CDATA[Last week, Array BioPharma (ARRY) announced that its most advanced, wholly-owned MEK inhibitor, ARRY-162, which was being developed to treat rheumatoid arthritis patients, failed to achieve a better response than placebo in a mid-stage trial. The study was designed to assess ARRY-162 in 201 patients with active rheumatoid arthritis who were not completely responsive to the drug methotrexate, the standard treatment. The subjects were on a stable dose of methotrexate for at least 6 weeks prior to their entry in the study. The 12-week study comprised of a placebo group and three different dose groups of ARRY-162. However, none of the treatment groups demonstrated a statistically significant response compared with the placebo group at 12 weeks. The placebo recipients in Latin America displayed much higher placebo response rates than patients ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/08/arry-setback-for-array-biopharmas-drug/14607/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GHDX) Good News for Genomic Health</title>
		<link>http://www.stockbloghub.com/2009/09/04/ghdx-good-news-for-genomic-health/14460</link>
		<comments>http://www.stockbloghub.com/2009/09/04/ghdx-good-news-for-genomic-health/14460#comments</comments>
		<pubDate>Fri, 04 Sep 2009 23:17:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14460</guid>
		<description><![CDATA[Yesterday, Genomic Health, Inc. (GHDX) announced that a number of leading U.S. surgeons ask for Genomic Health&#8217;s Oncotype DX breast cancer assay at the time of surgery or biopsy, in an effort to provide patients with prompt, critical information about treatment options available at their maiden visit to an oncologist. Oncotype DX, the growth engine of the company, was launched in 2004. It is the first and only multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In late May 2009, Genomic Health announced that more than 100,000 test results have been delivered in over 40 countries worldwide since the commercial launch of Oncotype DX. The assay analyzes the activity of 21 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/04/ghdx-good-news-for-genomic-health/14460/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARRY) Array Meets Expectations</title>
		<link>http://www.stockbloghub.com/2009/08/20/arry-array-meets-expectations-analyst-blog/12921</link>
		<comments>http://www.stockbloghub.com/2009/08/20/arry-array-meets-expectations-analyst-blog/12921#comments</comments>
		<pubDate>Thu, 20 Aug 2009 18:33:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Array BioPharma Inc.]]></category>
		<category><![CDATA[ARRY]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12921</guid>
		<description><![CDATA[Last week, Array BioPharma Inc. (ARRY) reported a fourth-quarter net loss of 55 cents per share which was in line with the Zacks Consensus Estimate. The company had a loss of 68 cents in the year-ago quarter. Net loss for fiscal 2009 was $2.67 per share, compared with $2.04 last year. Quarterly revenue came in at $5.5 million, representing a 10% decline from the comparable quarter in 2008. Sales for the full year fell by 13% to $25 million. The narrower quarterly loss was primarily attributable to lower spending on research and development. The company spent $21.3 million towards research and development for the quarter for the clinical advancement of its wholly owned drugs versus $28.4 million in year-ago quarter. Last January, Array had announced a restructuring plan of scaling ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/20/arry-array-meets-expectations-analyst-blog/12921/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BRLI) Bio-Reference Laboratories Inc. &#8211; In spite of the weak economy, revenue was up 16% from last year</title>
		<link>http://www.stockbloghub.com/2009/07/23/brli-bio-referance-laboratories-inc-in-spite-of-the-weak-economy-revenue-was-up-16-from-last-year/11136</link>
		<comments>http://www.stockbloghub.com/2009/07/23/brli-bio-referance-laboratories-inc-in-spite-of-the-weak-economy-revenue-was-up-16-from-last-year/11136#comments</comments>
		<pubDate>Thu, 23 Jul 2009 18:53:54 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Bio-Reference Laboratories Inc]]></category>
		<category><![CDATA[BRLI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=11136</guid>
		<description><![CDATA[Bio-Reference Laboratories Inc. (BRLI) is posting impressive gains in response to strong revenue growth and expanding margins. Company Description Bio-Reference Laboratories, provides clinical laboratory testing services such as blood and urine analysis in the New York metropolitan area. The company was founded in 1981 and has a market cap of $436 million. Shares of BRLI began rallying in early March with the overall market, but received a nice boost on June 4 when the company reported strong second-quarter results. Second-Quarter Results In spite of the weak economy, revenue was up 16% from last year to $87.2 million, a company record. Earnings came in at 33 cents per share, besting the consensus of 28 cents. Details Bio-Reference gained in a number of key statistical categories, posting a 17% improvement in gross ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/07/23/brli-bio-referance-laboratories-inc-in-spite-of-the-weak-economy-revenue-was-up-16-from-last-year/11136/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DGX) Quest Diagnostics Incorporated &#8211; Growth And Income &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/04/30/dgx-quest-diagnostics-incorporated-growth-and-income-zacks-rank-buy/6313</link>
		<comments>http://www.stockbloghub.com/2009/04/30/dgx-quest-diagnostics-incorporated-growth-and-income-zacks-rank-buy/6313#comments</comments>
		<pubDate>Thu, 30 Apr 2009 20:31:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=6313</guid>
		<description><![CDATA[Quest Diagnostics Incorporated (DGX) recently delivered strong first-quarter results. Earnings per share of 89 cents topped the year-prior 72 cents and exceeded analysts&#8217; expectations by 8.5%. Company Description Quest Diagnostics Incorporated provides diagnostic testing, information and services for patients and doctors all over the world. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers. Quest Diagnostics also provides interpretive consultation through its extensive medical and scientific staff. The company is consider to be a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. An Excellent Quarter Quest Diagnostics recently delivered strong first-quarter results. Earnings per share of 89 cents topped the year-prior 72 cents and exceeded analysts&#8217; expectations by 8.5%. First quarter ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/04/30/dgx-quest-diagnostics-incorporated-growth-and-income-zacks-rank-buy/6313/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BRLI) Bio-Reference Laboratories &#8211; This was the second consecutive quarter that the company has surprised and beat estimates</title>
		<link>http://www.stockbloghub.com/2008/12/26/brli-bio-reference-laboratories-this-was-the-second-consecutive-quarter-that-the-company-has-surprised-and-beat-estimates/1860</link>
		<comments>http://www.stockbloghub.com/2008/12/26/brli-bio-reference-laboratories-this-was-the-second-consecutive-quarter-that-the-company-has-surprised-and-beat-estimates/1860#comments</comments>
		<pubDate>Fri, 26 Dec 2008 23:49:19 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Bio-Reference Laboratories Inc]]></category>
		<category><![CDATA[BRLI]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=1860</guid>
		<description><![CDATA[Bio-Reference Laboratories, Inc. (BRLI) share price has been rallying since the company reported excellent fourth-quarter and full-year results last week. The next-year estimate has held steady, pegged at $1.48 per share, a n 8.5% earnings growth projection. Company Description Bio-Reference Laboratories, Inc. provides clinical laboratory testing services primarily in the greater New York metropolitan area. The company was founded in 1981 and has a market cap of $364 million. Fourth-Quarter Results Bio-Ref Labs chimed-in with impressive fourth-quarter and year-end results on Dec 18. Revenue for the quarter was up 16% from last year to $81.2 million. Income came in at $5.2 million, up from $4.6 million last year. This produced earnings of 38 cents per share, ahead of estimates by 2 cents. This was the second consecutive quarter that the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/12/26/brli-bio-reference-laboratories-this-was-the-second-consecutive-quarter-that-the-company-has-surprised-and-beat-estimates/1860/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

